

Martin BÃgsted

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2008359/publications.pdf>

Version: 2024-02-01

119
papers

2,323
citations

257450

24
h-index

276875

41
g-index

124
all docs

124
docs citations

124
times ranked

4150
citing authors

#	ARTICLE	IF	CITATIONS
1	Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography-â€˜Staged Treatment-Naive Patients With Hodgkin Lymphoma. Journal of Clinical Oncology, 2012, 30, 4508-4514.	1.6	252
2	Neutrophil Extracellular Traps in Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2052-2067.	1.9	131
3	Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis. Journal of Clinical Oncology, 2015, 33, 1379-1388.	1.6	94
4	Long Noncoding RNA Expression during Human B-Cell Development. PLoS ONE, 2015, 10, e0138236.	2.5	80
5	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danishâ€˜Swedish Population-Based Study. Journal of Clinical Oncology, 2015, 33, 3993-3998.	1.6	74
6	Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. Journal of Clinical Oncology, 2017, 35, 778-784.	1.6	72
7	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer, 2017, 75, 195-203.	2.8	65
8	miR-155 as a Biomarker in B-Cell Malignancies. BioMed Research International, 2016, 2016, 1-14.	1.9	56
9	The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica, 2016, 101, 1451-1459.	3.5	55
10	Utility of interim and end-of-treatment PET/CT in peripheral Tâ€˜cell lymphomas: A review of 124 patients. American Journal of Hematology, 2015, 90, 975-980.	4.1	51
11	Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive nonâ€˜Hodgkin and Hodgkin lymphoma. American Journal of Hematology, 2014, 89, 575-580.	4.1	49
12	Proteome Analysis of Rheumatoid Arthritis Gut Mucosa. Journal of Proteome Research, 2017, 16, 346-354.	3.7	48
13	High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. Experimental Hematology, 2016, 44, 238-246.e2.	0.4	46
14	Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer, 2015, 15, 235.	2.6	44
15	Probabilistic models for access strategies to dynamic information elements. Performance Evaluation, 2010, 67, 43-60.	1.2	36
16	Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives. Briefings in Bioinformatics, 2020, 21, 936-945.	6.5	35
17	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large Bâ€˜cell lymphoma is associated with poor outcomes and a high frequency of secondary <scp>CNS</scp> involvement. British Journal of Haematology, 2016, 175, 876-883.	2.5	34
18	The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines. Biomarker Research, 2016, 4, 12.	6.8	29

#	ARTICLE	IF	CITATIONS
19	Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 338-347.	1.5	28
20	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. <i>British Journal of Haematology</i> , 2016, 173, 236-244.	2.5	28
21	Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R- <i>IPI</i> , <i>IPI</i> , and <i>NCCN-IPI</i> . <i>Cancer Medicine</i> , 2018, 7, 114-122.	2.8	28
22	A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. <i>British Journal of Haematology</i> , 2015, 169, 435-444.	2.5	27
23	Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13.	2.1	27
24	Non-Synonymous Polymorphisms in the FCN1 Gene Determine Ligand-Binding Ability and Serum Levels of M-Ficolin. <i>PLoS ONE</i> , 2012, 7, e50585.	2.5	27
25	R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 1105-1113.	1.3	26
26	Superior Reproducibility of the Leading to Leading Edge and Inner to Inner Edge Methods in the Ultrasound Assessment of Maximum Abdominal Aortic Diameter. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 206-213.	1.5	26
27	Polymorphisms in the MASP1 Gene Are Associated with Serum Levels of MASP-1, MASP-3, and MAP44. <i>PLoS ONE</i> , 2013, 8, e73317.	2.5	26
28	MicroRNAs in B-cells: from normal differentiation to treatment of malignancies. <i>Oncotarget</i> , 2015, 6, 7-25.	1.8	24
29	Non-occupational exposure to asbestos is the main cause of malignant mesothelioma in women in North Jutland, Denmark. <i>Scandinavian Journal of Work, Environment and Health</i> , 2019, 45, 82-89.	3.4	24
30	Impact of ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. <i>Leukemia and Lymphoma</i> , 2014, 55, 2349-2355.	1.3	23
31	The Prevalence of Oropharyngeal Dysphagia in Danish Patients Hospitalised with Community-Acquired Pneumonia. <i>Dysphagia</i> , 2017, 32, 383-392.	1.8	23
32	Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank. , 2015, 88, 40-49.		22
33	Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 703-713.	1.6	22
34	Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2771-2776.	1.3	20
35	Normal Value Ranges for Central Retinal Thickness Asymmetry in Healthy Caucasian Adults Measured by SPECTRALIS SD-OCT Posterior Pole Asymmetry Analysis. , 2015, 56, 3875.		19
36	Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2815-2823.	1.3	19

#	ARTICLE	IF	CITATIONS
37	The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. <i>Acta Oncologica</i> , 2019, 58, 864-871.	1.8	19
38	MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 1185-1196.	5.2	19
39	High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients. <i>Oncotarget</i> , 2019, 10, 717-731.	1.8	19
40	Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell Lines. <i>PLoS ONE</i> , 2011, 6, e19322.	2.5	18
41	Retinal proteome changes following experimental branch retinal vein occlusion and intervention with ranibizumab. <i>Experimental Eye Research</i> , 2016, 152, 49-56.	2.6	18
42	Feasibility of a multimodal intervention on malnutrition in patients with lung cancer during primary anti-neoplastic treatment. <i>Clinical Nutrition</i> , 2021, 40, 525-533.	5.0	18
43	Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. <i>European Journal of Cancer</i> , 2020, 129, 50-59.	2.8	17
44	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2021, 144, 72-80.	2.8	17
45	Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition. <i>BMC Bioinformatics</i> , 2014, 15, 168.	2.6	16
46	Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy. <i>Leukemia and Lymphoma</i> , 2014, 55, 1251-1260.	1.3	15
47	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. <i>Experimental Hematology</i> , 2014, 42, 927-938.	0.4	15
48	On Jones et al.'s method for extending Bland-Altman plots to limits of agreement with the mean for multiple observers. <i>BMC Medical Research Methodology</i> , 2020, 20, 304.	3.1	14
49	Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e83252.	2.5	13
50	A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology. <i>Blood Advances</i> , 2018, 2, 1542-1546.	5.2	13
51	Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0190709.	2.5	13
52	Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2516-2523.	1.3	13
53	Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. <i>Cancer Medicine</i> , 2020, 9, 4395-4404.	2.8	13
54	Decomposing random sums: a nonparametric approach. <i>Annals of the Institute of Statistical Mathematics</i> , 2010, 62, 855-872.	0.8	12

#	ARTICLE	IF	CITATIONS
55	CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2014, 16, 475.	3.5	12
56	Bone Marrow Aspiration: A Randomized Controlled Trial Assessing the Quality of Bone Marrow Specimens Using Slow and Rapid Aspiration Techniques and Evaluating Pain Intensity. <i>Acta Haematologica</i> , 2016, 135, 81-87.	1.4	12
57	On estimating the time to statistical cure. <i>BMC Medical Research Methodology</i> , 2020, 20, 71.	3.1	12
58	Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival. <i>Leukemia and Lymphoma</i> , 2017, 58, 2695-2704.	1.3	11
59	Estimating the loss of lifetime function using flexible parametric relative survival models. <i>BMC Medical Research Methodology</i> , 2019, 19, 23.	3.1	11
60	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. <i>Acta Oncologica</i> , 2022, 61, 409-416.	1.8	11
61	Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor. <i>Briefings in Bioinformatics</i> , 2014, 15, 519-533.	6.5	10
62	Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. <i>BMC Immunology</i> , 2014, 15, 3.	2.2	10
63	Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa. <i>PLoS ONE</i> , 2017, 12, e0169286.	2.5	10
64	Is the accuracy of preoperative MRI stage in rectal adenocarcinoma influenced by tumour height?. <i>Acta Oncologica</i> , 2018, 57, 728-734.	1.8	10
65	Exploring the dietary protein intake and skeletal muscle during first-line anti-neoplastic treatment in patients with non-small cell lung cancer. <i>Clinical Nutrition ESPEN</i> , 2019, 34, 94-100.	1.2	10
66	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.	2.5	10
67	The application of human phase 0 microdosing trials: A systematic review and perspectives. <i>Leukemia and Lymphoma</i> , 2016, 57, 1281-1290.	1.3	9
68	MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. <i>BMC Cancer</i> , 2020, 20, 237.	2.6	9
69	Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000–2016: a Danish population-based study. <i>British Journal of Haematology</i> , 2021, 193, 482-487.	2.5	9
70	Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. <i>Non-coding RNA</i> , 2021, 7, 1.	2.6	9
71	Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study. <i>Blood Advances</i> , 2018, 2, 559-564.	5.2	8
72	Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. <i>Cancers</i> , 2020, 12, 312.	3.7	8

#	ARTICLE	IF	CITATIONS
73	Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients. PLoS ONE, 2016, 11, e0154256.	2.5	8
74	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow – A proof of concept study. PLoS ONE, 2018, 13, e0193249.	2.5	8
75	Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 3257-3266.	1.3	7
76	Circulating tumor necrosis factor- α and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 2476-2478.	1.3	7
77	hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. PLoS ONE, 2016, 11, e0163711.	2.5	7
78	Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP. British Journal of Haematology, 2016, 174, 876-886.	2.5	7
79	Little value of surveillance magnetic resonance imaging for primary <sc>CNS</sc> lymphomas in first remission: results from a Danish Multicentre Study. British Journal of Haematology, 2017, 176, 671-673.	2.5	7
80	Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma. British Journal of Haematology, 2018, 182, 297-301.	2.5	7
81	Early mobilisation of patients with community-acquired pneumonia reduce length of hospitalisation – a pilot study. Journal of Physical Therapy Science, 2018, 30, 926-932.	0.6	7
82	Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis. Scientific Reports, 2019, 9, 335.	3.3	7
83	Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction. Scientific Reports, 2021, 11, 24498.	3.3	7
84	Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates. BMC Bioinformatics, 2016, 17, 159.	2.6	6
85	Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas. Leukemia and Lymphoma, 2019, 60, 1580-1583.	1.3	6
86	Proteomics dataset: The colon mucosa from inflammatory bowel disease patients, gastrointestinal asymptomatic rheumatoid arthritis patients, and controls. Data in Brief, 2017, 15, 511-516.	1.0	5
87	Rehospitalisation and mortality after hospitalisation for oropharyngeal dysphagia and community-acquired pneumonia: A 1-year follow-up study. Cogent Medicine, 2017, 4, 1417668.	0.7	5
88	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood Advances, 2018, 2, 2400-2411.	5.2	5
89	The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. BMC Cancer, 2021, 21, 829.	2.6	5
90	Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study. Leukemia, 2018, 32, 2263-2303.	7.2	4

#	ARTICLE	IF	CITATIONS
91	Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study. PLoS ONE, 2018, 13, e0208180.	2.5	4
92	Dynamic Intracellular Metabolic Cell Signaling Profiles During Ag-Dependent B-Cell Differentiation. Frontiers in Immunology, 2021, 12, 637832.	4.8	4
93	High-dose thoracic radiation therapy for non-small cell lung cancer: a novel grading scale of radiation-induced lung injury for symptomatic radiation pneumonitis. Radiation Oncology, 2021, 16, 131.	2.7	4
94	Generalized parametric cure models for relative survival. Biometrical Journal, 2020, 62, 989-1011.	1.0	4
95	High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019. Clinical Epidemiology, 2021, Volume 13, 1085-1094.	3.0	4
96	A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment. Blood Advances, 2022, 6, 2549-2556.	5.2	4
97	Characterization of memory B cells from thymus and its impact for DLBCL classification. Experimental Hematology, 2016, 44, 982-990.e11.	0.4	3
98	A systematic review of molecular responses to cancer therapy in normal human mucosa. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 355-366.	0.4	3
99	Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. PLoS ONE, 2020, 15, e0229593.	2.5	3
100	Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. Expert Review of Hematology, 2020, 13, 655-668.	2.2	3
101	ccostr: An R package for estimating mean costs with censored data. Journal of Open Source Software, 2019, 4, 1593.	4.6	3
102	Molecular classification of tissue from a transformed non-Hodgkin's lymphoma case with unexpected long-time remission. Experimental Hematology and Oncology, 2017, 6, 3.	5.0	2
103	Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients. European Journal of Haematology, 2017, 98, 355-362.	2.2	2
104	In vivo calibration of the T2* cardiovascular magnetic resonance method at 1.5T for estimation of cardiac iron in a minipig model of transfusional iron overload. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 27.	3.3	2
105	A predictive model for bone marrow disease in cytopenia based on noninvasive procedures. Blood Advances, 2022, 6, 3541-3550.	5.2	2
106	Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region. BMC Health Services Research, 2020, 20, 1047.	2.2	1
107	Hematological cancer survivors' experiences of participating in a shared care follow-up: an exploratory interview study. Journal of Cancer Survivorship, 2021, 15, 620-629.	2.9	1
108	Is the accuracy of preoperative MRI stage in rectal carcinoma influenced by tumor height?. Journal of Clinical Oncology, 2016, 34, 514-514.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Estimating a common covariance matrix for network meta-analysis of gene expression datasets in diffuse large B-cell lymphoma. <i>Annals of Applied Statistics</i> , 2018, 12, .	1.1	1
110	Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 251.	2.4	1
111	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission “ results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. <i>BMC Cancer</i> , 2022, 22, 147.	2.6	1
112	To maintain or not, that is the question. <i>British Journal of Haematology</i> , 2016, 174, 321-322.	2.5	0
113	Blood on the tracks “ toward precision medicine. <i>Leukemia and Lymphoma</i> , 2016, 57, 1753-1754.	1.3	0
114	No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2798-2801.	1.3	0
115	Outlier robust modeling of survival curves in the presence of potentially time-varying coefficients. <i>Statistical Methods in Medical Research</i> , 2020, 29, 2683-2696.	1.5	0
116	Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. <i>Future Oncology</i> , 2021, 17, 3331-3341.	2.4	0
117	Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2021, 158, 248-250.	2.8	0
118	Subtyping of B-Cell Malignancies By B-Cell Subset Associated Gene Signatures (BAGS), Generated from Human Primary and Secondary Lymphoid Organs.. <i>Blood</i> , 2015, 126, 5347-5347.	1.4	0
119	A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma. , 2021, 4, 208-222.		0